Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2004-08-06
2011-11-01
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S244100, C424S258100, C424S260100
Reexamination Certificate
active
08048432
ABSTRACT:
Abstract of the Disclosure Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.
REFERENCES:
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4771127 (1988-09-01), Cryz et al.
patent: 5773007 (1998-06-01), Penney et al.
patent: 5849301 (1998-12-01), Lees
patent: 6207157 (2001-03-01), Gu et al.
patent: 6531131 (2003-03-01), Gu et al.
patent: 6607725 (2003-08-01), Gu et al.
patent: 6685949 (2004-02-01), Gu et al.
patent: 6756040 (2004-06-01), Peetermans et al.
patent: WO 93/13797 (1993-07-01), None
patent: WO 2005/037320 (2005-04-01), None
Chu, C., et al. Infection and Immunity, pp. 245-256, vol. 40, No. 1, 1983.
Bartoloni, A. et al. 1995 “Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide”Vaccine13:463-470.
Guo, Z. and Jennings, H. 2001 “Protein-polysaccharide conjugation” InMethods in Molecular Medicine, Meningococcal Vaccines: Methods and Protocols,Eds. Pollard, A.J. and Maiden, M.C.J., Humana Press Inc., Totowa, N.J. 66:49-54.
Jennings, H. eand Lugowski, C. 1981 “Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates”J. lmmunol.127:1011-1018.
Konadu, E. et al. 2000 “Phase 1 and 2 studies ofSalmonella entericaserovarParatyphiA O-specific polysacchaaride-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam ”Infect. lmmun.68:1529-1534.
Lee, C.-J. 2002 “Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry”Biologicals30:97-103.
Lees, A. et al. 1996 “Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents”Vaccine14:190-198.
Mulard, L. et al. 2002 “Vaccins polyosidiques”Ann. L'Institut Pasteur Act.12 :37-54.
Shafer, D. et al. 2000 “Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides”Vaccine18:1273-1281.
Communication from European Patent Office Pursuant to Article 94(3) EPC, Dated Jan. 17, 2008 in EP Application No. 04809568.1-2402.
Tutton, A.E. (1891) “The Isolation of Hydrazine.”Nature,1105:205-210.
Behr et al., “Asymmetric synthesis of potent glycosidase and very potent α-mannosidase inhibitors: 4-amino-4-deoxy-L-erythrose and 4-amino-4,5-dideoxy-L-ribose,”Tetrahedron59:543-553, 2003.
Byrd et al., “Preparation, Characterization, and Immunogenicity of Conjugate Vaccines Directed againstActinobacillus pleruopneumonaeVirulence Determinants,”Infection and Immunitypp. 3042-3051, Aug. 1992.
Cryz et al., “Pseudomonas aeruginosaImmunotype 5 Polysaccharide-Toxin A Conjugate Vaccine,”Infection and Immunitypp. 161-165, Apr. 1986.
Cryz et al., “Vaccine Potential ofPseudomonas aeruginosaO-Polysaccharide-Toxin A Conjugates,”Infection and Immunitypp. 1547-1551, Jul. 1987.
Cryz et al., “Synthesis and Characterization ofEscheria coliO18 O-Polysaccharide Conjugate Vaccines,”Infection and Immunitypp. 373-377, Feb. 1990.
Cryz et al., “Synthesis and Characterization of aPseudomonas aeruginosaAlginate-Toxin A conjugate Vaccine,”Infection and Immunitypp. 45-50, Jan. 1991.
Fattom et al., “Comparative Immunogenicity of Conjugates Composed of theStaphylococcus aureusType 8 Capsular Polysaccharide Bound to Carrier Proteins by Adipic Acid Dihydrazide orN-Succinimidyl-3-(2-Pyridyldithio) propionate,”Infection and Immunitypp. 584-589, Feb. 1992.
Gu et al., “Synthesis, Characterization and Immunologic Properties of Detoxified Lipooligosaccharide from NontypeableHaemophilus influenzaeConjugated to Proteins,”Infection and Immunitypp. 4047-4053, Oct. 1996.
Gu et al., “Synthesis and Characterization of Lipooligosaccharide-Based Conjugates as Vaccine Candidates forMoraxella(Branhamella)catarrhalis,” Infection and Immunitypp. 1891-1897, May 1998.
Gupta et al., “Phase I Evaluation ofVibrio choleraO1, Serotype Inaba, Polysaccharide-Cholera Toxin Conjugates in Adjust Volunteers,”Infection and Immunitypp. 3095-3099, Jul. 1998.
Konadu et al., “Synthesis, Characterization, and Immunological Properties in Mice of Conjugates Composed of Detoxified Lipopolysaccharide ofSalmonella paratyphiA Bound to Tetanus Toxoid, with Emphasis on the Role ofOAcetyls,”Infection and Immunitypp. 2709-2715, Jul. 1996.
Konadu et al., “Preparation, Characterization, and Immunological Properties in Mice ofEscherichia coliO157 O-Specific Polysaccharide-Protein Conjugate Vaccines,”Infection and Immunitypp. 3095-3099, Jul. 1998.
Kossaczka et al., “Synthesis and Immunological Properties of Vi and Di-O-Acetyl Pectin Protein Conjugates with Adipic Acid Dihydrazide as the Linker,”Infection and Immunitypp. 2088-2093, Jun. 1997.
Kossaczka et al., “Safety and Immunogenicity of VI Conjugate Vaccines for Typhoid Fever in Adults, Teenagers, and 2- to 4-Year Old Children in Vietnam,”Infection and Immunitypp. 5806-5810, Nov. 1999.
Kossaczka et al., “Vibrio cholera O139 Conjugate Vaccines: Synthesis and Immunogenicity of V. cholera O139 Capsular Polysaccharide Conjugates with Recombinant Diphtheria Toxin Mutant in Mice,”Infection and Immunitypp. 5037-5043, Sep. 2000.
Kuo et al., “Characterization of a Recombinant Pneumolysin and Its Use as a Protein Carrier for Pneumococcal Type 18C Conjugate Vaccines,”Infection and Immunitypp. 2706-2713, Jul. 1995.
Lagergard et al., “Synthesis and Immunological Properties of Conjugates Composed of Group B Streptococcus Type III Capsular Polysaccharides Covalently Bound to Tetanus Toxoid,”Infection and Immunitypp. 687-694, Mar. 1990.
Que et al., “Effect of Carrier Selection on Immunogenicity of Protein Conjugate Vaccines againstPlasmodium falciparumCircumsporozoites,”Infection and Immunitypp. 2645-2649, Oct. 1988.
Sarvamangala et al., “Cryptococcus neoformans Serotype A Glucuronoxylamannan-Protein Conjugate Vaccines: Synthesis, Characterization, and Immunogenicity,”Infection and Immunitypp. 3700-3707, Oct. 1991.
Schneerson et al., “Synthesis of a Conjugate Vaccine Composed of Pneumococcus Type 14 Capsular Polysaccharide Bound to Pertussis Toxin,”Infection and Immunitypp. 3528-3532, Sep. 1992.
Shen et al., “Group BStreptococcusCapsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccines Prepared by Different Methods for Intranasal Immunization,”Infection and Immunitypp. 297-306, Jan. 2001.
Office Action dated Oct. 7, 2009, from U.S. Appl. No. 10/566,898.
Frasch Carl E.
Lee Che-Hung Robert
Klarquist & Sparkman, LLP
Swartz Rodney P.
The United States of America as represented by the Secretary of
LandOfFree
Polysaccharide-protein conjugate vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polysaccharide-protein conjugate vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polysaccharide-protein conjugate vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285809